Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 395Neoplasms 350Carcinoma, Non-Small-Cell Lung 313Prostatic Neoplasms 264Colorectal Neoplasms 236Lung Neoplasms 204Multiple Myeloma 163Pancreatic Neoplasms 147Ovarian Neoplasms 146Neoplasm Metastasis 141Leukemia, Myeloid, Acute 138Melanoma 118Squamous Cell Carcinoma of Head and Neck 100Carcinoma, Renal Cell 93Stomach Neoplasms 92Recurrence 92Lymphoma 91Lymphoma, Non-Hodgkin 89Endometrial Neoplasms 89Carcinoma, Hepatocellular 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 87Glioblastoma 85Brain Neoplasms 84Head and Neck Neoplasms 77Glioma 76Uterine Cervical Neoplasms 75Urinary Bladder Neoplasms 72Sarcoma 70Leukemia, Lymphocytic, Chronic, B-Cell 70Hematologic Neoplasms 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuromyelitis Optica × 30 days × Clear all
NCT06680037 2026-05-18

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

TG Therapeutics, Inc.

Phase 1 Recruiting
100 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡